Skip to Content

Posts tagged with "Patents and IP"

  • Biological News

    CRISPR In the Courts

    Here’s an article from the Independent on the legal battles that are underway about CRISPR technology. On one level, it can be a somewhat ugly story, but it also shows how much of a discovery the technique has been, that people are willing to fight for the rights to it so vigorously. But it’s going… Read More
  • Patents and IP

    Eli Lilly vs. Canada

    Eli Lilly has been complaining the U. S. Government for a while about the Canadian regulatory authorities, after they invalidated the company’s patents for Strattera and Zyprexa a few years ago. Unfortunately for them, as Ed Silverman reports, the U. S. Trade Representative has refused to put Canada on the list of countries that don’t… Read More
  • Patents and IP

    Can You Patent A Natural Product? Prepare For a Different Answer

    So, can you patent naturally occurring substances, or not? That’s a rather complicated question, and some recent Supreme Court decisions have recomplicated it in US patent law. Mayo v. Prometheus and Assoc. Mol. Pathology v. Myriad Genetics. The latter, especially, has sent the PTO (and the IP lawyers) back to staring out their respective win… Read More
  • Drug Development

    A New Book on Scaffold Hopping

    I’ve been sent a copy of Scaffold Hopping in Medicinal Chemistry, a new volume from Wiley, edited by Nathan Brown of the Institute of Cancer Research in London. There are eighteen chapters – five on identifying and characterizing scaffolds to start with, ten on various computational approaches to scaffold-hopping, and three case histori… Read More
  • Chemical News

    Free Chemical Patent Searching

    Here’s some good news for open (free) access to chemical information. A company called SureChem was trying to make a business out of chemical patent information, but had to fold. They’ve donated their database to the EMBL folks, and now we have SureChEMBL. At the moment, that link is taking me to the former SureChem… Read More
  • Drug Development

    The Past Twenty Years of Drug Development, Via the Literature

    Here’s a new paper in PlOSOne on drug development over the past 20 years. The authors are using a large database of patents and open literature publications, and trying to draw connections between those two, and between individual drug targets and the number of compounds that have been disclosed against them. Their explanation of patents… Read More
  • Graduate School

    Suing Your Grad School, And Your Professor

    As anyone who’s negotiated with them knows, Harvard plays hardball when it comes to patent rights. But so do the university’s students, apparently. C&E News has a report on Mark Charest, a former graduate student in the Myers lab, who is suing the university over patent royalties. Myers, Charest, and others reported a new synthetic… Read More
  • Patents and IP

    Pay-to-Delay: Not Necessarily Illegal, But Not Long For The World

    The Supreme Court has another ruling that affects the drug industry: FTC v. Actavis took up the question of “pay to delay”, the practice of paying generic companies to go away and not challenge a branded drug. Actavis was in the process of bringing a version of Solvay’s AndroGel to market, claiming that the Solvay… Read More
  • Patents and IP

    The Supreme Court Rules on Myriad

    Just a little while ago, the Supreme Court issued a unanimous decision (rare these days) in the Myriad Genetics case. I summarized the state of play up until the most recent arguments here, and if you’re just getting up to speed on this issue, I’d read that post first. There are a lot of things… Read More
  • Patents and IP

    Deuterated Drugs: An Obvious Idea?

    Nature Medicine has an update on the deuterated drug landscape. There are several compounds in the clinic, and the time to the first marketed deuterium-containing drug is surely counting down. But, as mentioned at the end of that piece, another countdown that also must be ticking away is the one to the first lawsuit. There… Read More